Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3223]

ASH 2022: Next-generation targeted therapy zanubrutinib found superior to ibrutinib for CLL and SLL

ASH 2022: Next-generation targeted therapy zanubrutinib found superior to ibrutinib for CLL and SLL

ASH 2022: MajesTEC-2 trial of teclistamab-cqyv in combination with daratumumab and hyaluronidase-fihj and lenalidomide shows clinical activity in RRMM

ASH 2022: MajesTEC-2 trial of teclistamab-cqyv in combination with daratumumab and hyaluronidase-fihj and...

ASH 2022: New results from the phase 3 GLOW study of fixed-duration treatment with ibrutinib plus venetoclax demonstrate robust efficacy and sustained response in older, unfit patients with previously untreated chronic lymphocytic leukaemia

ASH 2022: New results from the phase 3 GLOW study of fixed-duration treatment with ibrutinib plus venetoclax...

ASH 2022: Venetoclax with CLIA highly effective in younger patients with newly diagnosed AML and high-risk MDS

ASH 2022: Venetoclax with CLIA highly effective in younger patients with newly diagnosed AML and high-risk MDS

ASH 2022: Chemotherapy-free regimen ponatinib plus blinatumomab effective in patients with newly diagnosed Ph+ ALL

ASH 2022: Chemotherapy-free regimen ponatinib plus blinatumomab effective in patients with newly diagnosed Ph+ ALL

ASH 2022: Older or high-risk patients with newly diagnosed AML respond well to triplet therapy

ASH 2022: Older or high-risk patients with newly diagnosed AML respond well to triplet therapy

ASH 2022: New data for talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, suggesting durable responses in patients with heavily pretreated multiple myeloma

ASH 2022: New data for talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, suggesting durable responses...

ASH 2022: Novel drug shows early promise in treating multiple myeloma

ASH 2022: Novel drug shows early promise in treating multiple myeloma

ASH 2022: Efficacy and subgroup analyses from MAIA study showing long-term results of daratumumab based regimen in newly diagnosed, transplant-ineligible MM

ASH 2022: Efficacy and subgroup analyses from MAIA study showing long-term results of daratumumab based regimen in...

ASH 2022: Researchers present new approach to understanding challenging CAR T-cell toxicities

ASH 2022: Researchers present new approach to understanding challenging CAR T-cell toxicities

More from ecancer